- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01498627
Cervarix Long-term Safety Surveillance (PGRx)
Cervarix Long-term Safety Surveillance Using the PGRx Information System (PGRx Study)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PGRx is an information system that intends to bridge the resource gap to assess the effect of a drug on the risk of adverse events that are infrequent and/or with a long delay of onset. It uses some characteristics of the ad hoc case-control or case-referent design, transposed on a prospective, on-going, population-based recruitment plan. This particular design is called here systematic case-referent design in contrast to the ad hoc case-control or case-referent methodology. The PGRx information system is based on the routine and targeted recruitment of cases of a series of pathologies, compared to population-based referents for the study of exposure to a wide variety of drugs. Drug exposure ascertainment is obtained from two different sources in the PGRx.
system: A) A structured patient interview (telephone-administered questionnaire) B) The medical data form with the computerized medical prescriptions (interview guide)
Studietype
Registrering (Faktiske)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Male and female
- Age 14 to 79 years-old (included)
- Patient residing in France
- Patient accepting to participate in the study
- Patient can read and respond to a telephone interview
Exclusion Criteria:
- Prior reported history of the disease
- Patient or Patient's parent cannot read the interview guide or answer a telephone interview questionnaire in French
- Refusal to participate
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Case-Control
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Case Group
Subjects in this group are incident cases (i.e.
newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
|
3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
PGRx information system
|
Control Group
Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
|
3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
PGRx information system
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
To assess whether the use of Cervarix® is associated with a modified risk of central demyelination.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of type 1 diabetes.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of cutaneous Lupus.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of inflammatory arthritis.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of idiopathic thrombocytopenic purpura.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of systemic lupus erythematosus.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of addendum for cutaneous lupus.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of myositis.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of dermatomyositis.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of Guillain-Barrre syndrome.
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of autoimmune thyroiditis
Tidsramme: At Month 36
|
At Month 36
|
To assess whether the use of Cervarix® is associated with a modified risk of Graves disease.
Tidsramme: At Month 36
|
At Month 36
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 112677
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Infeksjoner, papillomavirus
-
H. Lee Moffitt Cancer Center and Research InstituteMerck Sharp & Dohme LLCFullført
-
Laval UniversityFullførtHumant papillomavirusCanada
-
University Hospital, ToulouseFullførtHumant papillomavirusFrankrike
-
University of North Carolina, Chapel HillHarvard Medical School (HMS and HSDM); Pfizer; North Carolina Department...FullførtHumant papillomavirusForente stater
-
The AlfredMerck Sharp & Dohme LLCFullførtInfeksjon av humant papillomavirus | Humant papillomavirusAustralia
-
M.D. Anderson Cancer CenterHar ikke rekruttert ennåHumant papillomavirusForente stater
-
Kaiser PermanenteNational Cancer Institute (NCI)Rekruttering
-
Queen Mary University of LondonFullført
-
Lake Cumberland District Health DepartmentMerck Sharp & Dohme LLCFullførtHumant papillomavirusForente stater
-
The University of Hong KongQueen Mary Hospital, Hong KongUkjent
Kliniske studier på Cervarix
-
National Institute for Public Health and the Environment...AvsluttetInfeksjon av humant papillomavirus
-
Henry M. Jackson Foundation for the Advancement...Johns Hopkins University; Karolinska Institutet; University of Miami; Chulalongkorn... og andre samarbeidspartnereAktiv, ikke rekrutterende
-
GlaxoSmithKlineFullførtInfeksjoner, papillomavirusTyskland, Taiwan, Thailand, Canada, Italia
-
GlaxoSmithKlineFullførtSikkerhetsstudie av GSK Biologicals' HPV-vaksine (GSK-580299) hos friske kvinnelige forsøkspersoner.Infeksjoner, papillomavirusHong Kong
-
GlaxoSmithKlineFullførtInfeksjoner, papillomavirus | PapillomavirusvaksinerDanmark, Polen, Litauen
-
GlaxoSmithKlineFullførtInfeksjoner, papillomavirusForente stater, Canada
-
GlaxoSmithKlineFullført
-
GlaxoSmithKlineClinical Practice Research DatalinkFullførtInfeksjoner, papillomavirusStorbritannia
-
Public Health EnglandFullførtHPV-infeksjonerStorbritannia
-
GlaxoSmithKlineFullførtInfeksjoner, papillomavirusDen russiske føderasjonen, Singapore, Australia, Portugal